Canada's SR&ED (Scientific Research and Experimental Development) program just received its most significant expansion in decades. For CFOs, the headline is straightforward: the maximum annual refundable credit your company can access has doubled, and newly eligible expense categories mean your qualifying base is almost certainly larger than you think. Understanding SR&ED eligibility criteria and optimizing your refundable tax credits strategy is critical: If your company is investing in R&D and you're not actively optimizing your SR&ED claim strategy, you're leaving non-dilutive capital on the table.

What SR&ED Is — and Why It Belongs on Your Financial Roadmap

SR&ED is the federal government's primary mechanism for incentivizing R&D investment in Canada through systematic investigation and experimental development. For qualifying Canadian-controlled private corporations (CCPCs), it delivers a 35% refundable investment tax credit (ITC) on eligible expenditures, with combined federal and provincial credits that can exceed 50%.

That last word—refundable—is what makes this program uniquely valuable from a cash flow perspective. Unlike non-refundable credits that simply reduce tax owing, refundable SR&ED tax credit payments come back to your company as a cash, regardless of whether you're in a profit position. For growth-stage companies reinvesting heavily in product development to overcome technological uncertainty and achieve technological advancement,, that's a meaningful financing mechanism.

Since the program's inception, SR&ED has been one of Canada's core R&D tax incentives for supporting innovation. The 2026 enhancements represent the largest expansion of the refundable SR&ED benefit in the program's history.

The 2026 SR&ED Enhancements: What Changed and What It Means for You

Bill C-15, the Budget 2025 Implementation Act, received Royal Assent on March 26, 2026, enhancing the SR&ED program by increasing the federal expenditure limit and taxable capital phase-out thresholds for the enhanced 35% ITC, extending the enhanced credit to eligible Canadian public corporations (ECPCs), and restoring the eligibility of capital expenditures. These changes apply to taxation years beginning on or after December 16, 2024.

Here's what that means in dollar terms:

Higher expenditure limit. The annual expenditure limit for the enhanced 35% refundable SR&ED ITC has increased from $3 million to $6 million. Qualifying corporations may now earn up to $2.1 million in refundable credits annually, which is double the previous maximum.

Capital expenditures are back. Depreciable property and shared-use equipment acquired after December 16, 2024 and used 90% or more for SR&ED activities is now eligible for both the income deduction and the ITC component, subject to recapture rules. For companies investing in hardware, lab infrastructure, or specialized computing resources for R&D, this is a material change to your qualifying base.

Expanded public company access. For the first time, eligible Canadian public corporation entities can access the enhanced 35% refundable credit; a significant shift for ECPCs that were previously limited to the 15% non-refundable rate.

Faster processing. Starting April 2026, refundable claims can expect a 45-day processing target, with pre-approved claims processed within 90 days.

The CFO's SR&ED Checklist

These are the questions every CFO should be asking before the next claim cycle:

  1. Are we capturing all eligible expenditures?Qualifying expenditures include salaries and wages for employees directly engaged in eligible activities and support work, materials consumed in R&D work, SR&ED contractor payments, and (as of December 2024) capital equipment used primarily for R&D. Many companies systematically undercount contractor time and inter-departmental labour allocations, and fail to implement proper time tracking systems. Accurate payroll records are essential for substantiating these claims.
  2. Are we within the new phase-out thresholds?The enhanced 35% refundable rate phases out based on either taxable capital or gross revenue. The phase-out thresholds have been increased as part of the 2026 enhancements, creating new optimization opportunities for companies that were previously partially phased out. Your SR&ED advisor should model both the taxable capital and gross revenue calculations to identify the more favourable approach.
  3. Is our documentation audit-ready? The CRA's single largest trigger for claim adjustments is insufficient contemporaneous documentation. CRA is consistently requiring more contemporaneous records; that is, documentation created during the claim period, not reconstructed at filing time. This includes detailed project descriptions, supporting evidence of experimental procedures, books and records, electronic records, and comprehensive technical documentation demonstrating applied research or basic research activities that advance scientific knowledge. The financial risk of a poorly documented claim isn't just the credits at stake; it's the cost of a multi-year review, potential on-site visit or virtual review, and the dispute resolution process if you need to file a formal objection.
  4. Are we stacking federal and provincial credits?SR&ED stacks with provincial R&D programs. Depending on your province, that can meaningfully increase your effective rate. British Columbia, Ontario, Quebec, and other provinces each offer their own R&D credits on top of the federal program. A qualified SR&ED advisor should be modeling the combined return and ensuring tax compliance across all jurisdictions.
  5. Are we meeting filing deadlines and using the correct forms? Ensure your team understands the filing deadlines for Form T661 (the SR&ED Expenditures Claim) and maintains awareness of CRA guidelines outlined in T4088. Missing deadlines or incomplete submissions can delay your notice of assessment and impact cash flow projections. The administrative review and financial review processes conducted by the financial reviewer require complete, accurate submissions to avoid delays in the objection process.

Why Specialist Expertise Delivers Better Returns

Generic accounting firms treat SR&ED as one service among many. The result is claims that miss qualifying activities, undercount eligible expenditures, and lack the documentation depth to withstand CRA scrutiny through technical review or financial review processes. Tech-only platforms automate data collection but lack the human expertise to make the subjective judgment calls that separate a good SR&ED claim from a great one, particularly when navigating complex issues like experimental development criteria or written representations during the objection process.

Boast's model is different: AI-powered data collection and claim management, paired with dedicated SR&ED specialists who review every claim. Since 2011, Boast has helped more than 2,000 companies across North America secure over $900M in R&D tax credits, and a 100% audit defense commitment backed by SOC II-compliant documentation.

Ready to maximize your 2026 SR&ED return? Get a free assessment from Boast's SR&ED specialists and find out how the 2026 enhancements affect your claim.

 

About Boast: Boast combines AI-powered technology with specialized human expertise to help Canadian and U.S. companies maximize their access to non-dilutive government funding. Founded in 2011, Boast has served 2,000+ companies and secured $900M+ in R&D tax credits across North America.